Inflammatory Bowel Disease Prevalence in Patients with Hidradenitis Suppurativa Using Prospective Symptom-Based Questionnaires and Fecal Calprotectin Testing.

IF 4.2 3区医学 Q1 DERMATOLOGY

Dermatology and Therapy Pub Date : 2025-07-01 Epub Date: 2025-05-25 DOI:10.1007/s13555-025-01438-7

Niamh Kearney, Emily K Pender, Rosalind Hughes, Collette McCourt, Graham Turner, Graham Morrison, Glen Doherty, Juliette Sheridan, Donal O'Kane, Brian Kirby

{"title":"Inflammatory Bowel Disease Prevalence in Patients with Hidradenitis Suppurativa Using Prospective Symptom-Based Questionnaires and Fecal Calprotectin Testing.","authors":"Niamh Kearney, Emily K Pender, Rosalind Hughes, Collette McCourt, Graham Turner, Graham Morrison, Glen Doherty, Juliette Sheridan, Donal O'Kane, Brian Kirby","doi":"10.1007/s13555-025-01438-7","DOIUrl":null,"url":null,"abstract":"Introduction: Hidradenitis suppurativa (HS) is associated with inflammatory bowel disease (IBD). Using healthcare databases, an estimated 2.1% of patients with HS have IBD. Prospective screening of patients with HS with IBD sign/symptom-based questions and fecal calprotectin (FC) has not been studied. Our aim was to evaluate the prevalence of IBD in HS and the utility of a sign/symptom-based questionnaire and FC testing.Methods: All patients with HS attending two clinics were invited to participate. Information was collected on demographics, HS severity, and IBD risk factors. Fecal samples were returned by patients for calprotectin testing (≤ 50 μg/g = negative, 50-150 μg/g = borderline, ≥ 150 μg/g = positive).Results: We recruited 150 patients including 124 women (82.7%) with a median age of 36 years and Hurley stage 2/3 disease (88.6%); 11 patients had established IBD (7.3%). Up to 44.7% of patients reported gastrointestinal symptoms. In 98 patients who returned a fecal sample for calprotectin measurement, 10 had previously diagnosed IBD (10.3%), 81 had a negative FC (82.7%), 13 had a borderline FC (13.3%) and 4 had a positive FC (4.1%). Among 4 patients with a positive result, 2 had known IBD (50%); 2 without established IBD were referred to gastroenterology and 1 had a negative endoscopy reporting an acute diarrheal illness at the time of their FC. The second patient was diagnosed with endoscopic and histologic Crohn's disease.Conclusions: We report an IBD prevalence of 8%, higher than previous studies. Routine IBD sign/symptom-based assessment is currently recommended. In our study, this would result in a referral rate of 44.7%. Among 88 FC tests in patients without established IBD, 1 patient was diagnosed with incident occult Crohn's disease. At a number needed to screen (NNS) of 88, routine evaluation of all patients with HS with FC may be justified especially prior to the use of interleukin (IL)-17 antagonists.","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1901-1913"},"PeriodicalIF":4.2000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126381/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01438-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Hidradenitis suppurativa (HS) is associated with inflammatory bowel disease (IBD). Using healthcare databases, an estimated 2.1% of patients with HS have IBD. Prospective screening of patients with HS with IBD sign/symptom-based questions and fecal calprotectin (FC) has not been studied. Our aim was to evaluate the prevalence of IBD in HS and the utility of a sign/symptom-based questionnaire and FC testing.

Methods: All patients with HS attending two clinics were invited to participate. Information was collected on demographics, HS severity, and IBD risk factors. Fecal samples were returned by patients for calprotectin testing (≤ 50 μg/g = negative, 50-150 μg/g = borderline, ≥ 150 μg/g = positive).

Results: We recruited 150 patients including 124 women (82.7%) with a median age of 36 years and Hurley stage 2/3 disease (88.6%); 11 patients had established IBD (7.3%). Up to 44.7% of patients reported gastrointestinal symptoms. In 98 patients who returned a fecal sample for calprotectin measurement, 10 had previously diagnosed IBD (10.3%), 81 had a negative FC (82.7%), 13 had a borderline FC (13.3%) and 4 had a positive FC (4.1%). Among 4 patients with a positive result, 2 had known IBD (50%); 2 without established IBD were referred to gastroenterology and 1 had a negative endoscopy reporting an acute diarrheal illness at the time of their FC. The second patient was diagnosed with endoscopic and histologic Crohn's disease.

Conclusions: We report an IBD prevalence of 8%, higher than previous studies. Routine IBD sign/symptom-based assessment is currently recommended. In our study, this would result in a referral rate of 44.7%. Among 88 FC tests in patients without established IBD, 1 patient was diagnosed with incident occult Crohn's disease. At a number needed to screen (NNS) of 88, routine evaluation of all patients with HS with FC may be justified especially prior to the use of interleukin (IL)-17 antagonists.

查看原文本刊更多论文

使用前瞻性症状问卷和粪便钙保护蛋白检测的化脓性汗腺炎患者的炎症性肠病患病率

化脓性汗腺炎（HS）与炎症性肠病（IBD）相关。根据医疗数据库，估计有2.1%的HS患者患有IBD。有IBD体征/症状问题和粪便钙保护蛋白（FC）的HS患者的前瞻性筛查尚未进行研究。我们的目的是评估HS中IBD的患病率以及基于体征/症状的问卷调查和FC测试的实用性。方法：邀请所有在两个诊所就诊的HS患者参与研究。收集了人口统计学、HS严重程度和IBD危险因素的信息。患者返回粪便标本进行钙保护蛋白检测（≤50 μg/g为阴性，50-150 μg/g为交界，≥150 μg/g为阳性）。结果：我们招募了150例患者，其中124例女性（82.7%），中位年龄36岁，Hurley 2/3期疾病（88.6%）；11例患者已建立IBD（7.3%）。高达44.7%的患者报告了胃肠道症状。在98例返回粪便样本进行钙保护蛋白检测的患者中，10例先前诊断为IBD(10.3%)， 81例FC阴性（82.7%），13例边缘性FC(13.3%)， 4例FC阳性（4.1%）。4例阳性患者中，2例已知IBD (50%)；2名未确诊IBD的患者被转介到胃肠病学，1名在FC时内窥镜检查呈阴性，报告急性腹泻病。第二例患者经内窥镜和组织学诊断为克罗恩病。结论：我们报告IBD患病率为8%，高于之前的研究。目前推荐常规IBD体征/症状评估。在我们的研究中，这将导致44.7%的转诊率。在未确诊IBD患者的88例FC检查中，1例患者被诊断为偶发隐匿性克罗恩病。筛查所需的数字（NNS）为88，对所有HS合并FC患者进行常规评估可能是合理的，特别是在使用白细胞介素(IL)-17拮抗剂之前。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.